Synthesis and characterization of Fulvestrant and Paclitaxel conjugates with polyamidoamine dendrimer fourth generation
DOI:
https://doi.org/10.15584/ejcem.2023.3.1Keywords:
PAMAM dendrimer, double-conjugation, Fulvestrant, Paclitaxel, anticancer drug delivery systemAbstract
Introduction and aim. Poorly soluble anticancer drugs can be attached covalently into biologically inert macromolecule in order to administrate a drug as water soluble form. It was proven that covalent linkers, for instance amide or carbamate bonds are susceptible to hydrolysis. Thus the attached drug can be released from the conjugates in tissue, specifically within the targeted cell. We aimed at construction of water soluble conjugates of Fulvestrant and Paclitaxel with PAMAM G4 dendrimer. In order to obtain water soluble conjugates the amine groups were substituted with R-glycidol.
Material and methods. Polyamidoamine dendrimer of fourth generation was synthesized and examined by detailed NMR analysis in water and in DMSO. The conjugates were covalently linked to amine groups of PAMAM after activation of Fulvestrant 17-OH group with 4-nitrophenylchloroformate and activation of end-carboxyl group of Paclitaxel succinate.
Results. The method of binary conjugate PAMAMG4-Fulvestrant-Paclitaxel synthesis was elaborated and the product was characterized by physicochemical methods.
Conclusion. The glycidylated PAMAMG4-Fulvestrant-Paclitaxel conjugate is better soluble in water than unconverted drugs.
Supporting Agencies
The research was funded by University of Rzeszów from General Status Activity Fund.Downloads
References
www.cancer.org/research/cancer-facts-statistics/. Accessed February 14, 2023.
World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed February 14, 2023.
Debela DT, Muzazu SG, Heraro KD, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021; 9:20503121211034366. doi: 10.1177/20503121211034366
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71. doi: 10.1186/s12951-018-0392-8
Oddone N, Lecot N, Fernández M, et al. In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer. J Nanobiotechnol. 2016;14:45. doi: 10.1186/s12951-016-0197-6
Abedi-Gaballu F, Dehghan G, Ghaffari M, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018;12:177-190. doi: 10.1016/j.apmt.2018.05.002
Dichwalkar T, Patel S, Bapat S, et al. Omega-3 Fatty Acid Grafted PAMAM-Paclitaxel Conjugate Exhibits Enhanced Anticancer Activity in Upper Gastrointestinal Cancer Cells. Macromol Biosci. 2017;17:1600457. doi: 10.1002/mabi.201600457
Lewińska A, Wróbel K, Błoniarz D, et al. Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status. Biomater Adv. 2022;140:213047. doi: 10.1016/j.bioadv.2022.213047
Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677-2681. doi: 10.1091/mbc.E14-04-0916
Zasadil LM, Andersen KA, Yeum D, et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014;6(229):229ra43. doi: 10.1126/scitranslmed.3007965
Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D. Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. Biomolecules. 2019;9(12):789. doi: 10.3390/biom9120789
Haldar S, Chintapalli J, Croce CM. Taxol Induces bcl-2 Phosphorylation and Death of Prostate Cancer Cells. Cancer Res. 1996;56:1253-1255.
Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli, R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Delivery. 2010;17(6):419-425. doi: 10.3109/10717541003777233
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf. Accessed February 27, 2023.
Nathan MR, Schmid P. A Review of Fulvestrant in Breast Cancer. Oncol Ther. 2017;5(1):17-29. doi: 10.1007/s40487-017-0046-2
Johnston SJ, Cheung KL. Fulvestrant - a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17(10):902-914. doi: 10.2174/092986710790820633
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005. doi:10.1016/s0140-6736(16)32389-3
Rocca A, Maltoni R, Bravaccini S, Donati C, Andreis D. Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. Cancer Manag Res. 2018;10:3083-3099. doi: 10.2147/CMAR.S137772
Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-38043. doi: 10.18632/oncotarget.16723
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743. doi: 10.1056/NEJMoa064320
Wróbel K, Wołowiec S, Markowicz J, Wałajtys-Rode E, Uram Ł. Synthesis of biotinylated PAMAM G3 dendrimers substituted 2 with R-glycidol and celecoxib/simvastatin as repurposed drugs and demonstration of their increased additive cytotoxicity for cancer cell lines. Cancers. 2022;14 (3):714. doi: 10.3390/cancers14030714
Uram Ł, Filipowicz-Rachwał A, Misiorek M, Winiarz A, Wałajtys-Rode E, Wołowiec S. Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimers Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells. Biomolecules. 2019;9:437. doi: 10.3390/biom9090437
Tomalia D, Baker H, Dewald J, et al. A new Class of Polymers: Starburst-Dendritic Macromolecules. Polym J. 1985;17:117-132.
Satsangi A, Roy SS, Satsangi RK, Vadlamudi, RK, Ong JL. Design of a Paclitaxel Prodrug Conjugate for Active Targeting of an Enzyme Upregulated in Breast Cancer Cells. Mol Pharmaceutics. 2014;11:1906-1918. doi: 10.1021/mp500128k
Wróbel K, Wołowiec S. Low generation polyamidoamiine dendrimers (PAMAM) and biotin PAMAM conjugate – the detailed structural studies by 1H and 13C nuclear magnetic resonance spectroscopy. Eur J Clin Exp Med. 2020;18:281-285. doi: 10.15584/ejcem.2020.4.4
Malinga-Drozd M, Uram Ł, Wróbel K, Wołowiec S. Chiral recognition of homochiral poly(amidoamine) dendrimers substituted with R- and S-glycidol by keratinocyte (HaCaT) and squamous carcinoma (SCC-15) cells in vitro. Polymers. 2021;13:1049. doi: 10.3390/polym13071049
Cline EN, Li M-H, Choi SK, et al. Paclitaxel-Conjugated PAMAM Dendrimers Adversely Affect Microtubule Structure through Two Independent Modes of Action. Biomacromolecules. 2013;14:654-664. doi: 10.1021/bm301719b
Teow HM, Zhou ZY, Najlah M, Yusof SR, Abbott NJ, D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm. 2012;441:701-711. doi: 10.1016/j.ijpharm.2012.10.024
Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017;8(16):3131-3141. doi: 10.7150/jca.18457
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
